IRADIMED CORPORATION Revenue from Contract with Customer, Excluding Assessed Tax
IRADIMED CORPORATION (IRMD) reported Revenue from Contract with Customer, Excluding Assessed Tax of $20.47 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-31.
Financial Statements › Income Statement › Revenue
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax · last filed 2026-07-31
- IRADIMED CORPORATION revenue from contract with customer, excluding assessed tax for the quarter ending 2026-06-30 was $20.47M, a 0.28% increase year-over-year.
- IRADIMED CORPORATION revenue from contract with customer, excluding assessed tax for the quarter ending 2026-03-31 was $21.98M, a 12.65% increase year-over-year.
- IRADIMED CORPORATION revenue from contract with customer, excluding assessed tax for the quarter ending 2025-12-31 was $22.69M, a 17.03% increase year-over-year.
- IRADIMED CORPORATION revenue from contract with customer, excluding assessed tax for the quarter ending 2025-09-30 was $21.20M, a 15.69% increase year-over-year.
- IRADIMED CORPORATION revenue from contract with customer, excluding assessed tax for fiscal 2025 was $83.81M, a 14.43% increase from fiscal 2024.
- IRADIMED CORPORATION revenue from contract with customer, excluding assessed tax for fiscal 2024 was $73.24M, a 11.71% increase from fiscal 2023.
- IRADIMED CORPORATION revenue from contract with customer, excluding assessed tax for fiscal 2023 was $65.56M, a 23.00% increase from fiscal 2022.
- IRADIMED CORPORATION revenue from contract with customer, excluding assessed tax for fiscal 2022 was $53.30M, a 27.48% increase from fiscal 2021.
| Period end | Revenue from Contract with Customer, Excluding Assessed Tax 3 month | Revenue from Contract with Customer, Excluding Assessed Tax 3 month as first filed | Revenue from Contract with Customer, Excluding Assessed Tax 6 month | Revenue from Contract with Customer, Excluding Assessed Tax 6 month as first filed | Revenue from Contract with Customer, Excluding Assessed Tax 9 month | Revenue from Contract with Customer, Excluding Assessed Tax 12 month | Revenue from Contract with Customer, Excluding Assessed Tax 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $20.47M 10-Q · filed 2026-07-31 | $42.44M 10-Q · filed 2026-07-31 | $65.14M derived: sum of 3 quarters · filed 2026-07-31 | $86.34M derived: sum of 4 quarters · filed 2026-07-31 | |||
| 2026-03-31 | $21.98M 10-Q · filed 2026-05-01 | $44.67M derived: sum of 2 quarters · filed 2026-05-01 | $65.87M derived: sum of 3 quarters · filed 2026-05-01 | $86.28M derived: sum of 4 quarters · filed 2026-07-31 | |||
| 2025-12-31 | $22.69M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-06 | $43.89M derived: sum of 2 quarters · filed 2026-03-06 | $64.30M derived: sum of 3 quarters · filed 2026-07-31 | $83.81M 10-K · filed 2026-03-06 | |||
| 2025-09-30 | $21.20M 10-Q · filed 2025-11-03 | $41.61M derived: sum of 2 quarters · filed 2026-07-31 | $61.12M 10-Q · filed 2025-11-03 | $80.51M derived: sum of 4 quarters · filed 2026-07-31 | |||
| 2025-06-30 | $20.41M 10-Q · filed 2026-07-31 | $20.41M 10-Q · filed 2025-08-01 | $39.92M 10-Q · filed 2026-07-31 | $39.92M 10-Q · filed 2025-08-01 | $59.31M derived: sum of 3 quarters · filed 2026-07-31 | $77.64M derived: sum of 4 quarters · filed 2026-07-31 | |
| 2025-03-31 | $19.51M 10-Q · filed 2026-05-01 | $19.51M 10-Q · filed 2025-05-05 | $38.90M derived: sum of 2 quarters · filed 2026-05-01 | $57.23M derived: sum of 3 quarters · filed 2026-05-01 | $75.15M derived: sum of 4 quarters · filed 2026-05-01 | ||
| 2024-12-31 | $19.39M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-06 | $37.72M derived: sum of 2 quarters · filed 2026-03-06 | $55.64M derived: sum of 3 quarters · filed 2026-03-06 | $73.24M 10-K · filed 2026-03-06 | $73.24M 10-K · filed 2025-03-06 | ||
| 2024-09-30 | $18.33M 10-Q · filed 2025-11-03 | $36.25M derived: sum of 2 quarters · filed 2025-11-03 | $53.85M 10-Q · filed 2025-11-03 | $71.31M derived: sum of 4 quarters · filed 2025-11-03 | |||
| 2024-06-30 | $17.93M 10-Q · filed 2025-08-01 | $35.53M 10-Q · filed 2025-08-01 | $52.98M derived: sum of 3 quarters · filed 2025-09-03 | $69.48M derived: sum of 4 quarters · filed 2025-09-03 | |||
| 2024-03-31 | $17.60M 10-Q · filed 2025-05-05 | $35.05M derived: sum of 2 quarters · filed 2025-09-03 | $51.55M derived: sum of 3 quarters · filed 2025-09-03 | $67.69M derived: sum of 4 quarters · filed 2025-09-03 | |||
| 2023-12-31 | $17.45M derived: 10-K/A 12 month − 10-Q 9 month · filed 2025-09-03 | $33.96M derived: sum of 2 quarters · filed 2025-09-03 | $50.09M derived: sum of 3 quarters · filed 2025-09-03 | $65.56M 10-K/A · filed 2025-09-03 | |||
| 2023-09-30 | $16.50M 10-Q · filed 2024-10-31 | $32.64M derived: sum of 2 quarters · filed 2024-10-31 | $48.11M 10-Q · filed 2024-10-31 | $62.97M derived: sum of 4 quarters · filed 2024-10-31 | |||
| 2023-06-30 | $16.13M 10-Q · filed 2024-08-01 | $31.61M 10-Q · filed 2024-08-01 | $46.47M derived: sum of 3 quarters · filed 2024-08-01 | $59.88M derived: sum of 4 quarters · filed 2024-08-01 | |||
| 2023-03-31 | $15.48M 10-Q · filed 2024-05-02 | $30.34M derived: sum of 2 quarters · filed 2024-05-02 | $43.75M derived: sum of 3 quarters · filed 2024-05-02 | $56.47M derived: sum of 4 quarters · filed 2024-05-02 | |||
| 2022-12-31 | $14.86M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-01 | $28.27M derived: sum of 2 quarters · filed 2024-03-01 | $40.99M derived: sum of 3 quarters · filed 2024-03-01 | $53.30M 10-K · filed 2024-03-01 | |||
| 2022-09-30 | $13.41M 10-Q · filed 2023-11-03 | $26.13M derived: sum of 2 quarters · filed 2023-11-03 | $38.44M 10-Q · filed 2023-11-03 | $50.31M derived: sum of 4 quarters · filed 2023-11-03 | |||
| 2022-06-30 | $12.72M 10-Q · filed 2023-08-03 | $25.03M 10-Q · filed 2023-08-03 | $36.91M derived: sum of 3 quarters · filed 2023-08-03 | $47.81M derived: sum of 4 quarters · filed 2023-08-03 | |||
| 2022-03-31 | $12.31M 10-Q · filed 2023-05-04 | $24.18M derived: sum of 2 quarters · filed 2023-05-04 | $35.09M derived: sum of 3 quarters · filed 2023-05-04 | $44.90M derived: sum of 4 quarters · filed 2023-05-04 | |||
| 2021-12-31 | $11.87M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-02 | $22.78M derived: sum of 2 quarters · filed 2023-03-02 | $32.59M derived: sum of 3 quarters · filed 2023-03-02 | $41.81M 10-K · filed 2023-03-02 | |||
| 2021-09-30 | $10.91M 10-Q · filed 2022-11-03 | $20.72M derived: sum of 2 quarters · filed 2022-11-03 | $29.94M 10-Q · filed 2022-11-03 | $38.49M derived: sum of 4 quarters · filed 2022-11-03 | |||
| 2021-06-30 | $9.81M 10-Q · filed 2022-08-05 | $19.03M 10-Q · filed 2022-08-05 | $27.58M derived: sum of 3 quarters · filed 2022-08-05 | $35.28M derived: sum of 4 quarters · filed 2022-08-05 | |||
| 2021-03-31 | $9.22M 10-Q · filed 2022-05-06 | $17.77M derived: sum of 2 quarters · filed 2022-05-06 | $25.47M derived: sum of 3 quarters · filed 2022-05-06 | $32.26M derived: sum of 4 quarters · filed 2022-05-06 | |||
| 2020-12-31 | $8.55M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-04 | $16.25M derived: sum of 2 quarters · filed 2022-03-04 | $23.04M derived: sum of 3 quarters · filed 2022-03-04 | $31.72M 10-K · filed 2022-03-04 | |||
| 2020-09-30 | $7.70M 10-Q · filed 2021-11-05 | $14.49M derived: sum of 2 quarters · filed 2021-11-05 | $23.17M 10-Q · filed 2021-11-05 | $34.06M derived: sum of 4 quarters · filed 2022-03-04 | |||
| 2020-06-30 | $6.79M 10-Q · filed 2021-08-06 | $15.47M 10-Q · filed 2021-08-06 | $26.36M derived: sum of 3 quarters · filed 2022-03-04 | $36.33M derived: sum of 4 quarters · filed 2022-03-04 | |||
| 2020-03-31 | $8.68M 10-Q · filed 2021-05-07 | $19.57M derived: sum of 2 quarters · filed 2022-03-04 | $29.53M derived: sum of 3 quarters · filed 2022-03-04 | $38.76M derived: sum of 4 quarters · filed 2022-03-04 | |||
| 2019-12-31 | $10.89M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-04 | $20.85M derived: sum of 2 quarters · filed 2022-03-04 | $30.08M derived: sum of 3 quarters · filed 2022-03-04 | $38.52M 10-K · filed 2022-03-04 | |||
| 2019-09-30 | $9.96M 10-Q · filed 2020-11-06 | $19.19M derived: sum of 2 quarters · filed 2020-11-06 | $27.63M 10-Q · filed 2020-11-06 | $35.97M derived: sum of 4 quarters · filed 2021-03-05 | |||
| 2019-06-30 | $9.23M 10-Q · filed 2020-08-06 | $17.66M 10-Q · filed 2020-08-06 | $26.00M derived: sum of 3 quarters · filed 2021-03-05 | $33.62M derived: sum of 4 quarters · filed 2021-03-05 | |||
| 2019-03-31 | $8.44M 10-Q · filed 2020-05-07 | $16.78M derived: sum of 2 quarters · filed 2021-03-05 | $24.39M derived: sum of 3 quarters · filed 2021-03-05 | $31.77M derived: sum of 4 quarters · filed 2021-03-05 | |||
| 2018-12-31 | $8.34M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-05 | $15.95M derived: sum of 2 quarters · filed 2021-03-05 | $23.33M derived: sum of 3 quarters · filed 2021-03-05 | $30.44M 10-K · filed 2021-03-05 | |||
| 2018-09-30 | $7.61M 10-Q · filed 2019-11-07 | $14.99M derived: sum of 2 quarters · filed 2019-11-07 | $22.10M 10-Q · filed 2019-11-07 | $28.80M derived: sum of 4 quarters · filed 2020-03-06 | |||
| 2018-06-30 | $7.38M 10-Q · filed 2019-08-07 | $14.48M 10-Q · filed 2019-08-07 | $21.19M derived: sum of 3 quarters · filed 2020-03-06 | $26.88M derived: sum of 4 quarters · filed 2020-03-06 | |||
| 2018-03-31 | $7.11M 10-Q · filed 2019-05-08 | $13.81M derived: sum of 2 quarters · filed 2020-03-06 | $19.50M derived: sum of 3 quarters · filed 2020-03-06 | $25.03M derived: sum of 4 quarters · filed 2020-03-06 | |||
| 2017-12-31 | $6.70M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-06 | $12.39M derived: sum of 2 quarters · filed 2020-03-06 | $17.92M derived: sum of 3 quarters · filed 2020-03-06 | $23.08M 10-K · filed 2020-03-06 | |||
| 2017-09-30 | $5.69M 10-Q · filed 2018-11-07 | $11.21M derived: sum of 2 quarters · filed 2018-11-07 | $16.38M 10-Q · filed 2018-11-07 | ||||
| 2017-06-30 | $5.52M 10-Q · filed 2018-08-08 | $10.69M 10-Q · filed 2018-08-08 | |||||
| 2016-12-31 | $32.50M 10-K · filed 2019-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TANDEM DIABETES CARE INC (TNDM) | United States | $1.059B | -16.57 |
| ARTIVION, INC. (AORT) | United States | $1.123B | -345.09 |
| PROCEPT BioRobotics Corp (PRCT) | United States | $1.001B | -11.77 |
| Beta Bionics, Inc. (BBNX) | United States | $0.979B | -9.66 |
| INTEGRA LIFESCIENCES HOLDINGS CORP (IART) | United States | $1.234B | -193.02 |
| SpyGlass Pharma, Inc. (SGP) | United States | $0.925B | |
| SI-BONE, Inc. (SIBN) | United States | $0.830B | -49.82 |
| MIMEDX GROUP, INC. (MDXG) | United States | $0.687B | 89.92 |
| Alphatec Holdings, Inc. (ATEC) | United States | $1.531B | -12.14 |
| KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) | United States | $1.535B | -9.02 |